Please Wait...

Michael W. Weiner

Translation skills

Main profile

Michael W. Weiner, MD
Senior Scientific Advisor

Michael Weiner, MD, is a Professor in Residence in Radiology and Biomedical Engineering, Medicine, Psychiatry, and Neurology at the University of California, San Francisco.  He is Principle Investigator of the Alzheimer's Disease Neuroimaging Initiative (ADNI) and served as the Director of the Center for Imaging of Neurodegenerative Diseases (CIND) at the San Francisco Veterans Affairs Medical Center for nearly 10 years.

After graduating from the Johns Hopkins University in 1961, He obtained his MD from SUNY Upstate Medical Center in Syracuse, New York in 1965, and he completed his internship and residency in Medicine from Mt. Sinai Hospital in 1967.  From 1967-1968, Dr. Weiner completed a residency and clinical fellowship in Metabolism from Yale-New Haven Medical Center.  In 1970, he completed a research fellowship in Nephrology from Yale University School of Medicine and a research fellowship in Biochemistry from the University of Wisconsin Institute for Enzyme Research in 1972, followed by a joint appointment in the Department of Medicine; Renal Section from the University of Wisconsin Institute in 1972.  In 1974 he became an Assistant Professor of Medicine (Nephrology) at Stanford University, and in 1980 he became an Associate Professor of Medicine (Nephrology) at UCSF.  In 1983 he established the Magnetic Resonance Unit at the San Francisco VA Medical Center, which became the Center for Imaging of Neurodegenerative Diseases in 2004.  In 1990 he became a Professor of Radiology, Medicine, Psychiatry and Neurology at UCSF.

Dr. Weiner's research activities involve the development and utilization of MRI and PET for investigating and diagnosing neurodegenerative diseases.  In 1980, Dr. Weiner was one of the first to perform MRS on an intact animal, and subsequently pursued his goal to develop MRI/S as a clinical tool.  Over the past 25 years, he has worked to develop and optimize the use of MRI, PET, and blood based biomarker methods to diagnose Alzheimer's disease and other neurodegenerative disorders.

Dr. Weiner's research focuses on monitoring effects of treatment to slow progressions in Alzheimer's disease and the early detection of Alzheimer's disease in patients.  He has also launched The Brain Health Registry, which is a web-based registry for recruiting, screening, and longitudinally monitoring subjects for neuroscience studies of all types.  Dr. Weiner has over 650 published articles and has authored over 70 book chapters.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @ACROhealth: @MaryWolleyRA Mary Woolley @ResearchAmerica: 80% have heard of #clinicaltrials. 75% think trial participation is as importa…
bioclinica (3 days ago)
#Pharma & CROs: Ck it out! Enterprise tools for site payments automation & reconciliation. https://t.co/LFri5Kv0WC
bioclinica (3 days ago)
Can having a geographically diverse network of high performing sites mean fewer sites are needed in a trial? Can ha… https://t.co/tZYvWrNzHg
bioclinica (3 days ago)
Confidence is a good thing ─ especially in the clinical supply chain for global clinical trials. Here’s how accurat… https://t.co/70VwXCwuWw
bioclinica (4 days ago)
#Pharmacovigilance: Get up-to-speed on latest ind. trends & best practices + hear how others R meeting today's most… https://t.co/3YNpB9hTXs
bioclinica (1 week ago)
Announcing our new Chief of Staff @bioclinica Adrienne Rossi! Also welcoming President Bioclinica Site Network Eliz… https://t.co/toB9yk534k
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen